All In MedTech

Device Trial Radar · NCT06976086

Pediatric Expansion Study of the Sentio System

A Prospective, Multicenter, Single-arm Clinical Investigation of the Safety and Performance of the Sentio System in a Pediatric Population

Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Apr 30, 2025

Primary completion

Oct 1, 2026

Study completion Jul 1, 2027

Sponsor

Lead sponsor
Oticon MedicalNot on our public-company list
Sponsor type
Industry
Collaborators
Guy's and St Thomas' NHS Foundation Trust; Birmingham Women's and Children's NHS Foundation Trust; Great Ormond Street Hospital for Children NHS Foundation Trust; University Medical Center Groningen; Radboud University Medical Center; Hospital Universitario La Fe; Hospital Universitario Virgen Macarena; Hospital Donostia
First posted
May 16, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 3 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is performed to collect safety and performance data supporting the use of the Sentio system in children below 12 years of age. The system is currently available on the market for patients 12 years and above. It is a prospective study conducted at eight European hospitals, aiming to treat 50 patients with a hearing loss than would benefit from treatment with a bone-anchored hearing system (BAHS). The primary objective of the study is to demonstrate that the Sentio system improves the hearing on the implanted ear, compared with the unaided situation.

Conditions

  • Hearing Loss, Conductive
  • Hearing Loss, Mixed
  • Single Sided Deafness

Interventions

  • Active transcutaneous bone conduction systemDevice

    The Sentio system consists of the Sentio 1 Mini sound processor (SP) and Sentio Ti implant with fixation band and screws.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Demonstrate that the Sentio system improves hearing on the implanted ear.Time frame: 3 months post-surgery

Locations

8 sites in 3 countries. Site status is shown where the registry gives one.

  • University Medical Center Groningen

    Groningen, Netherlands

  • Radboud University Medical Center

    Nijmegen, Netherlands

  • Hospital Universitario de Donostia

    San Sebastián, Spain

5 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.